NCT02359292View on ClinicalTrials.gov

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 30, 2015

Study Completion Date

July 31, 2015

Conditions
Asthma
Interventions
DRUG

CHF 5993 HS 200/6/25 pMDI

DRUG

CHF 5993 MS 100/6/25 pMDI

DRUG

CHF 5993 HS 200/6/25 pMDI + Charcoal Block

DRUG

CHF 5993 MS 100/6/25 pMDI + Charcoal Block

DRUG

Placebo pMDI

Trial Locations (1)

Unknown

SGS CPU Antwerpen, Antwerp

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT02359292 - Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers | Biotech Hunter | Biotech Hunter